Is BioNTech (BNTX) Too Pricey for Its Current Sales Base?

BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether today’s valuation rests on a solid revenue base or on expectations that are hard to pin down. Over the past 5 years the share price has fallen 71.5%, which puts the spotlight firmly on whether the current...